Cyteir Therapeutics Inc (CYT) Form 4 Filed by Venrock Associates VII, L.P. and 2 Others, Jun 23, 2021
SEC Form 4 · No Market Transaction
Conversion
Conversion of derivative securities.
Reporting Owners
TXN 2021-06-22
·
FILED 2021-06-23
Equity Position
3.26M sh
0 → 3,259,025
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owners
| Name | Relationship |
|---|---|
| Venrock Associates VII, L.P. CIK 0001614766 |
10% Owner
|
| Venrock Partners VII, L.P. CIK 0001614765 |
10% Owner
|
| Venrock Management VII, LLC CIK 0001614686 |
10% Owner
|
Non-Derivative Securities Transactions
Derivative Securities Transactions
Footnotes (2)
- F1
- Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. Show more
- F2
- Consists of 3,009,710 shares of Common Stock held by Venrock Associates VII, L.P. ("VA VII") and 249,315 shares of Common Stock held by Venrock Partners VII, L.P. ("VP VII"). Venrock Management VII, LLC ("VM VII") is the sole general partner of VA VII and VP VII and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA VII and VP VII except to the extent of its indirect pecuniary interest therein. Show more
Related filings at Cyteir Therapeutics Inc
Institutional Holders
13F holders · Mar 31, 2024
4
institutional managers reporting a position
Largest by reported value
Other insiders at Cyteir Therapeutics Inc
GET /v1/forms/4/0001209191-21-042724
API docs
View Original SEC Filing